Clinical characteristics and outcomes of the 10 Ph+ ALL patients
| Patient . | Age, y/sex . | Date of diagnosis . | Induction treatment . | Maintenance . | Type of response under IM (duration, mo) . | Salvage treatment . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 84/F | November 2003 | IM 600 mg/d + PDN | IM 600 mg/d | CMR (65) | — | A&W |
| 2 | 73/M | October 2005 | IM 600 mg/d + PDN | IM 600 mg/d | CHR (11) | — | Death from other causes* |
| 3† | 59/F | February 2004 | DNM + PDN + VCR + L-Asp | IM 800 mg/d | Molecular relapse (36) | Switch to second-generation TKIs | A&W |
| 4 | 69/F | December 2006 | IM 800 mg/d + PDN | IM 800 mg/d | CHR (41) | — | A&W |
| 5 | 71/M | November 2002 | IM 800 mg/d + PDN | IM 800 mg/d | CHR (37) | — | Death from other causes‡ |
| 6† | 42/F | January 2005 | DNM + PDN + VCR + L-Asp | IM 800 mg/d | Hematologic relapse (5) | AlloSCT | Death from leukemia relapse |
| 7 | 25/F | September 2008 | IM 600 mg/d + PDN | IM 600 mg/d | CHR (8) | — | A&W |
| 8 | 61/F | March 2008 | IM 600 mg/d + PDN | IM 800 mg/d | CHR (12) | — | A&W |
| 9 | 68/F | May 2002 | DNM + PDN + VCR + L-Asp | IM 800 mg/d | MRD increasing values (52) | Switch to second-generation TKIs | A&W |
| 10 | 63/M | June 2009 | IM 600 mg/d + PDN | IM 800 mg/d | CHR (4) | — | A&W |
| Patient . | Age, y/sex . | Date of diagnosis . | Induction treatment . | Maintenance . | Type of response under IM (duration, mo) . | Salvage treatment . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 84/F | November 2003 | IM 600 mg/d + PDN | IM 600 mg/d | CMR (65) | — | A&W |
| 2 | 73/M | October 2005 | IM 600 mg/d + PDN | IM 600 mg/d | CHR (11) | — | Death from other causes* |
| 3† | 59/F | February 2004 | DNM + PDN + VCR + L-Asp | IM 800 mg/d | Molecular relapse (36) | Switch to second-generation TKIs | A&W |
| 4 | 69/F | December 2006 | IM 800 mg/d + PDN | IM 800 mg/d | CHR (41) | — | A&W |
| 5 | 71/M | November 2002 | IM 800 mg/d + PDN | IM 800 mg/d | CHR (37) | — | Death from other causes‡ |
| 6† | 42/F | January 2005 | DNM + PDN + VCR + L-Asp | IM 800 mg/d | Hematologic relapse (5) | AlloSCT | Death from leukemia relapse |
| 7 | 25/F | September 2008 | IM 600 mg/d + PDN | IM 600 mg/d | CHR (8) | — | A&W |
| 8 | 61/F | March 2008 | IM 600 mg/d + PDN | IM 800 mg/d | CHR (12) | — | A&W |
| 9 | 68/F | May 2002 | DNM + PDN + VCR + L-Asp | IM 800 mg/d | MRD increasing values (52) | Switch to second-generation TKIs | A&W |
| 10 | 63/M | June 2009 | IM 600 mg/d + PDN | IM 800 mg/d | CHR (4) | — | A&W |
AlloSCT indicates allogeneic stem cell transplantation; A&W, alive and well; CHR, complete hematologic remission; CMR, complete molecular remission; DNM, daunorubicin; IM, imatinib mesylate; L-Asp, L-asparaginase; MRD, minimal residual disease; PDN, prednisone; Ph+ ALL, Philadelphia chromosome–positive acute lymphoblastic leukemia; TKIs, tyrosine kinase inhibitors; VCR, vincristine, and —, not applicable.
Cerebral ischemia, stroke, and acute renal failure.
Patient undergoing a consolidation treatment with high-dose cytarabine and mitoxantrone.
Chronic renal failure and congestive heart failure.